Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 6;6(8):101113.
doi: 10.1016/j.jhepr.2024.101113. eCollection 2024 Aug.

Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis

Elton Dajti  1   2 , Susana G Rodrigues  3 , Federica Perazza  2 , Luigi Colecchia  2 , Giovanni Marasco  2   4 , Matteo Renzulli  5 , Giovanni Barbara  1   2 , Francesco Azzaroli  1   2 , Annalisa Berzigotti  3 , Antonio Colecchia  6 , Federico Ravaioli  2   7
Affiliations

Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis

Elton Dajti et al. JHEP Rep. .

Abstract

Background & aims: Sarcopenia is associated with increased morbidity and mortality in patients with cirrhosis, but its definition in current literature is very heterogeneous. We performed a systematic review and meta-analysis to assess the association between mortality and sarcopenia evaluated by computed tomography (CT) in patients with cirrhosis, both overall and stratified for the criteria used to define sarcopenia.

Methods: Medline, Embase, Scopus, and Cochrane Library were searched up to January 2023. We included studies assessing sarcopenia presence with CT scans and providing data on the risk of mortality. Adjusted hazard ratios (HRs) and 95% CIs were pooled using a random-effects model.

Results: Thirty-nine studies comprising 12,827 patients were included in the meta-analysis. The summary prevalence of sarcopenia was 44% (95% CI 38-50%). The presence of sarcopenia (any definition) was an independent predictor of mortality with an adjusted HR of 2.07 (95% CI 1.81-2.36), and the result was consistent in all subgroup analyses. The prognostic role of the EASL/AASLD criteria was confirmed for the first time with an HR of 1.86 (95% CI 1.53-2.26) (n = 14 studies). The cut-offs used to define sarcopenia based on psoas muscle parameters varied among studies, thus, a subgroup analysis was not feasible. There was no substantial heterogeneity for the main estimates and no significant risk of publication bias.

Conclusions: Sarcopenia on CT is associated with a 2-fold higher risk of mortality in patients with cirrhosis. The cut-offs proposed by EASL/AASLD are prognostically relevant and should be the recommended criteria used to define sarcopenia in clinical practice.

Impact and implications: Sarcopenia assessed by the reference standard (computed tomography scan) is an independent predictor of mortality in patients with cirrhosis, with a 2-fold increase in the risk of death in all sensitivity analyses. This finding is particularly valid in patients from Europe and North America, and in transplant candidates. Stratifying for the parameters and cut-offs used, we confirmed for the first time the prognostic impact of the definition proposed by EASL/AASLD, supporting their use in clinical practice. Psoas muscle assessment is promising, but data are still limited and too heterogeneous to recommend its routine use at present.

Keywords: liver transplantation; malnutrition; meta-analysis; sarcopenia; skeletal muscle index; survival.

PubMed Disclaimer

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
PRISMA flowchart for included studies. HCC, hepatocellular carcinoma; TIPS, transjugular portosystemic shunt.
Fig. 2
Fig. 2
Association between mortality and sarcopenia defined according to published skeletal muscle cut-offs.
Fig. 3
Fig. 3
Association between mortality and sarcopenia defined according to published cut-offs based on psoas muscle.
See this image and copyright information in PMC

References

    1. Cruz-Jentoft A.J., Bahat G., Bauer J., et al. Sarcopenia: revised European consensus on definition and diagnosis european working group on sarcopenia in older people 2 (EWGSOP2), and the extended group for EWGSOP2. Age Ageing. 2019;48:16–31. - PMC - PubMed
    1. Tandon P., Montano-Loza A.J., Lai J.C., et al. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75:S147–S162. - PMC - PubMed
    1. Tapper E.B., Nikirk S., Parikh N.D., et al. Falls are common, morbid, and predictable in patients with cirrhosis. J Hepatol. 2021;75(3):582. - PMC - PubMed
    1. Marasco G., Dajti E., Ravaioli F., et al. Clinical impact of sarcopenia assessment in patients with liver cirrhosis. Expert Rev Gastroenterol Hepatol. 2021;15(4):377–388. - PubMed
    1. Ge J., Kim W.R., Lai J.C., et al. Beyond MELD” - emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation. J Hepatol. 2022;76(6):1318–1329. - PMC - PubMed